For stroke survivors and their families, resulting consequences such as partial paralysis and gait impairment impose a significant burden on daily life.
However, in recent years, a novel regenerative medicine approach, known as Stem Cell Therapy, has garnered attention as a beacon of hope for individuals suffering from post-stroke sequelae.
Specifically, treatment utilizing Wharton's Jelly-derived stem cells (WJ-MSC) from the placenta and umbilical cord has demonstrated promising recovery reports.
Post-Stroke Care and Current Treatment Challenges
When an individual experiences a stroke (cerebral infarction or cerebral hemorrhage), common sequelae often include unilateral paralysis, leading to impaired mobility, or difficulty with fluent speech articulation.
In modern medicine, acute treatment immediately following a stroke includes fibrinolytic therapy (medication to dissolve blood clots) and catheter-based endovascular interventions, which have rapidly advanced and saved many lives.
However, no treatment method has yet been proven to radically repair cerebral neurons and tissue damaged by stroke.
As a result, advanced symptoms such as paralysis often persist for extended periods, and even with rehabilitation, recovery frequently plateaus over time.
In fact, many patients continue to experience paralysis or language impairments over prolonged periods, necessitating long-term care and thereby imposing a significant burden on both patients and their families.
The inability to sufficiently ameliorate this post-stroke disability has become a significant challenge, and expectations for novel treatment methods are increasingly growing.
Stem Cell Therapy for Post-Stroke Management and New Possibilities in Regenerative Medicine
Stem Cell Therapy, a branch of regenerative medicine, has garnered attention in efforts to address post-stroke sequelae.
Regenerative medicine, simply put, is a therapeutic approach that aims to restore damaged tissues and organs within the body.
Stem Cell Therapy is a method involving the introduction of cells—either autologous (derived from the patient) or allogeneic (from another donor)—into the body to achieve the restoration of lost tissue function.
Stem cells are capable of differentiating into various tissues, and cells from diverse sources have been investigated, including bone marrow, adipose tissue, placenta, and umbilical cord obtained at birth.
Among these, mesenchymal stem cells (WJ-MSCs) extracted from a jelly-like tissue known as "Wharton's Jelly" in the umbilical cord have garnered significant attention in recent years.
Wharton's Jelly-derived stem cells are umbilical cord cells, readily collected at birth, that exhibit a low propensity for immune rejection even when transplanted into allogeneic recipients.
These stem cells can be envisioned as possessing a protective barrier that shields them from the maternal immune system during gestation. This characteristic also confers low immunogenicity, meaning they are not readily attacked or rejected by the immune system even when transplanted into another individual.
By utilizing WJ-MSCs, which possess such superior properties, treatment can be administered without the difficulty or burden of autologous cell harvesting.
Global research into post-stroke stem cell therapies is currently underway, and there is now the potential for patients to achieve neurological functional recovery previously unattainable with conventional treatments.
For example, stem cells are administered into the body via intravenous (IV) injection or by inserting a needle through the hip bone into the cerebrospinal fluid space (intrathecal administration) to repair damaged brain.
If conventional rehabilitation therapy is an approach to "maximizing residual function", then Stem Cell Therapy is an approach that aims toHealing the damaged part itself.
This groundbreaking regenerative therapy has unlocked new possibilities for patients and families suffering from post-stroke sequelae.
Mechanism of Action of Stem Cell Therapy for Post-stroke Sequelae
So, how specifically can stem cells introduced into the body repair brain damage? The mechanism of action of Stem Cell Therapy, in short, isAwaken the dormant self-healing power in the damaged brain.
Self-injected stem cells can grow and replace necessary cells (e.g., nerve cells), but more importantly isMany "recovery-promoting substances" secreted by stem cells.
Imagine the brain as a garden.
In the 'garden' ravaged by the 'storm' of a stroke, weeds (harmful inflammation) proliferate, and essential plants (nerve cells) are unable to flourish.
Subsequently, the newcomers—stem cells—arrive as farmers, removing weeds (ameliorating the tissue microenvironment), distributing fertilizer (growth factors), and facilitating the growth of new leaves (new nerve cells and blood vessels).
The primary anticipated effects of Stem Cell Therapy are as follows.
Suppressing inflammation and preparing a healing environment.
Stem cells congregate at the site of damage and secrete substances that mitigate the exaggerated inflammatory response and modulate immune homeostasis. This serves to quench the "inflammatory fire" in the damaged brain and create an environment conducive to healing.
This reduces secondary neuronal damage and establishes a foundation for recovery.
Promoting the regeneration of blood vessels and new nerve cells.
Growth factors and cytokines secreted by potent stem cells promote angiogenesis (new capillary formation) and nerve regeneration.
For example, brain-derived neurotrophic factor (BDNF) and hepatocyte growth factor (HGF) released from stem cells have been shown to protect damaged neurons and promote new neurite outgrowth.
This recirculates blood and nutrients to the damaged brain, promoting the survival and growth of the neurons.
Facilitating the reorganization of brain neural networks.
Stem Cell Therapy is expected to promote the remodeling and reconnection of disrupted neural circuits in the brain.
In animal experiments, it has been reported that stem cells promote the formation of new synaptic connections between neurons. This is akin to reconstructing signal transmission pathways, including the establishment of alternative routes.
As a result, it became possible for the remaining brain regions to assume new roles and compensate for functions, for example, by controlling paralyzed limbs through alternative pathways.
Completing the missing cell.
Despite their limited number, there are indications that injected stem cells may differentiate into neural or vascular cells, thereby replacing damaged ones. In essence, they directly replenish the compromised cell population.
However, current understanding suggests that rather than the stem cells themselves persisting long-term in the brain and continuing to function, the primary effects are believed to be mediated by substances released by the stem cells (referred to as secretome).
In animal experiments, it has been reported that even after transplanted stem cells eventually disappear from the body, considerable therapeutic effects persist, attributed to substances secreted during their presence.
In this way, stem cells become"pabrik obat"itself and releases the necessary substances, subtly supporting the brain's self-healing.
Evidence of the Effectiveness of Stem Cell Therapy in Post-Stroke Patients
The effectiveness of Stem Cell Therapy in improving post-stroke sequelae has become increasingly evident through various recent clinical studies. A majority of early-phase clinical trials (Phase I/II) conducted worldwide have reported promising results.
We will now present some of the scientific evidence.
Example of improvement through repeated intervention in chronic stroke patients:
A clinical study was conducted in which patients in the chronic phase, several months to years after stroke onset, were treated multiple times with stem cells derived from Wharton's Jelly.
In this study, when stem cells were periodically injected into the cerebrospinal fluid space (the fluid-filled area surrounding the spinal cord, typically accessed via the lumbar region), improvements in language disorders were observed in some cases, with speech becoming clearer. Additionally, cases of enhanced motor function in paralyzed limbs were also reported.
Indeed, all treated patients demonstrated an an improvement in their level of functional independence in daily living activities compared to baseline, and a subset of patients also exhibited improvements in communication abilities.
In contrast, in the control group that only received standard conventional treatment, only a small proportion of patients showed significant improvement during the same period. Furthermore, it is noteworthy that no serious side effects were reported with this Stem Cell Therapy.
At the one-year follow-up post-treatment, safety and effectiveness were maintained.
Report on functional recovery through intravenous administration:
In separate clinical trials, following intravenous administration of stem cells to post-stroke patients and subsequent monitoring of their progress, the stem cell recipient group demonstrated significant improvements in neurological deficit scores (NIH Stroke Scale) and functional independence in activities of daily living (Barthel Index and Modified Rankin Scale).
According to the report, the Stem Cell Therapy group demonstrated a statistically significant improvement in function even when compared to the control group (placebo recipients), with no serious adverse events observed. This study was conducted as a double-blind, placebo-controlled trial, thereby ensuring the high scientific reliability of its findings.
Research and other reviews:
Furthermore, improvements in motor function and neurological symptoms attributable to Stem Cell Therapy have been consistently reported across numerous clinical studies of varying scales conducted globally.
For example, even in trials conducted by Japanese and Korean groups using autologous bone marrow-derived stem cells, improvements in paralysis have been indicated. Additionally, in acute stroke trials conducted in the West, it has also been reported that patients treated with stem cells demonstrated improved functional prognoses.
Based on this accumulating evidence, Stem Cell Therapy is demonstrating the potential for improvement in residual paralysis, even after continuous rehabilitation.
Specifically, Wharton's Jelly-derived mesenchymal stem cells (WJ-MSCs) possess a wide array of secreted substances (cytokines, growth factors, etc.) and high immunomodulatory capabilities, thus demonstrating significant potential for repairing post-stroke damage.
Experimentally, WJ-MSCs have been found to exhibit a potent neuroprotective function (neuroprotection). In clinical studies, results comparable to, or even more promising than, those from stem cells of other origins have been obtained.
As clinical trials involving a larger number of cases are set to continue, the effectiveness of WJ-MSC will be further demonstrated.
Safety of Stem Cell Therapy in Post-Stroke Patients and Adverse Effects
When undergoing new treatments, safety is a paramount consideration.
Fortunately, across numerous clinical trials of Stem Cell Therapy to date, very few serious adverse events have been reported.
Specifically, Wharton's Jelly-derived stem cells, as previously mentioned, exhibit low immunogenicity. Consequently, even when utilizing allogeneic cells, they do not readily elicit severe rejection reactions or serious immunological complications.
In clinical research, serious inflammatory or allergic reactions following stem cell administration have not been observed.
While it cannot be definitively stated that there are absolutely no side effects, the majority of reported side effects are temporary and mild. For example, in patients who received stem cells via infusion, there have been isolated cases of transient fever or headache. These symptoms are typically temporary and resolve without complications with appropriate management.
Upon intrathecal administration of stem cells in the lumbar spine, a transient headache may occur, similar to that experienced following a lumbar puncture. This symptom typically resolves within a few days.
It is important to note that stem cells themselves are inherently resistant to malignant transformation (cancer), and there have been no reported instances of stem cells transplanted in prior clinical applications causing new tumor formation.
Stem cells are believed not to proliferate uncontrollably within the body. Instead, after a defined period, they fulfill their functions and subsequently diminish.
Furthermore, even when using allogeneic stem cells extracted from umbilical cord blood or tissue, donor screening (e.g., infection tests) and strict quality management are performed during cell cultivation.
Cells isolated and expanded from provided umbilical cords undergo safety testing compliant with GMP (Good Manufacturing Practices). Only cells successfully passing these tests are approved for therapeutic use. Through this rigorous process, the risk of infection and foreign body contamination is mitigated to an extremely low level.
Overall, stem cell therapy can be considered a treatment method with a high safety profile.
Currently, no serious life-threatening risks have been reported, and it is assessed that there is minimal significant concern for patients.
Safety of Stem Cell Therapy in Post-Stroke Patients and Adverse Effects
Safety assurance is a critical factor when initiating new treatments.
Fortunately, in various clinical trials of Stem Cell Therapy to date, almost no serious adverse events have been reported.
Specifically, Wharton's Jelly-derived stem cells, as previously mentioned, are immunoprivileged. This characteristic means that even when allogeneic cells are used, serious rejection reactions and immune complications are unlikely to occur.
In fact, in clinical studies, no severe inflammatory or allergic reactions have been observed following stem cell administration.
It must be acknowledged that it is not entirely without side effects; however, the majority are temporary and mild. For instance, cases have been reported where patients receiving stem cells intravenously experienced transient fever or headache. These effects were temporary and resolved effectively with appropriate management.
Following the administration of stem cells via the lumbar spine, a transient headache may occur, similar to that experienced during a lumbar puncture, but this typically resolves within a few days.
It should be noted that stem cells themselves possess characteristics that do not readily undergo malignant transformation, and there have been no reports to date that stem cells injected in clinical applications have caused de novo tumor formation.
Stem cells are believed not to continuously proliferate excessively within the body; rather, they will diminish after a specific period, once their designated role has been fulfilled.
Furthermore, even when utilizing allogeneic stem cells derived from umbilical cord blood or tissue, comprehensive donor screening (e.g., infectious disease testing) and rigorous quality control during cell expansion are conducted.
Cells isolated and expanded from donated umbilical cords undergo safety testing in accordance with GMP (Good Manufacturing Practice), and only those that pass are used for therapeutic purposes. Through this process, the risk of infection and foreign material contamination is rigorously minimized.
Overall, stem cell therapy is a therapeutic approach with a high safety profile.
No serious life-threatening risks are currently reported, and it is believed there is minimal major concern for the patient.
Conclusion
Stem Cell Therapy for post-stroke patients is garnering significant promise as a medical treatment offering renewed hope for the restoration of functions previously deemed irrecoverable.
The prospect of regaining movement in paralyzed limbs or recovering lost speech provides invaluable encouragement to patients.
Stem cell therapy remains an evolving frontier in medicine; however, research is being vigorously pursued both nationally and internationally, and it is not unrealistic to envision that in the future, it will become one of the standard therapeutic options.
In fact, among those receiving treatment, cases have begun to emerge demonstrating invaluable improvements in quality of life, such as "I can walk again on my own two feet" and "I can speak with my family."
For patients and their families suffering from post-stroke sequelae, Stem Cell Therapy is a beacon of hope.
Researchers and medical professionals continue to work diligently every day to ensure that this light grows ever brighter and more expansive in the future.
Even if a complete cure is not anticipated, a dormant regenerative capacity resides within the body. Stem Cell Therapy may assist in awakening this potential.
We earnestly hope that through the advancement of this regenerative medicine, an increasing number of stroke survivors will be able to regain lost function and reintegrate into daily life with renewed vitality and optimism.